Table 3.
Association of SIRI and Neoadjuvant Chemotherapy or Postoperative Chemotherapy
| Parameters | Low SIRI＜0.85 | High SIRI≥0.85 | χ2 | P value | |
|---|---|---|---|---|---|
| Cases (n) | 262 | 155 (59.2%) | 107 (40.8%) | ||
| Neoadjuvant chemotherapy regimen | 15.269 | 0.004 | |||
| AC/ACF | 27 (10.3%) | 17 | 10 | ||
| CT/ACT | 29 (11.1%) | 22 | 7 | ||
| AT | 121 (46.2%) | 78 | 43 | ||
| TP | 75 (28.6%) | 31 | 44 | ||
| Others | 10 (3.8%) | 7 | 3 | ||
| Chemotherapy times | 0.531 | 0.466 | |||
| ＜6 | 85 (32.4%) | 53 | 32 | ||
| ≥6 | 177 (67.6%) | 102 | 75 | ||
| Response | 2.105 | 0.716 | |||
| CR | 5 (1.9%) | 3 | 2 | ||
| PR | 156 (59.5%) | 91 | 65 | ||
| SD | 94 (35.9%) | 55 | 39 | ||
| PD | 7 (2.7%) | 6 | 1 | ||
| Miller and Payne grade | 4.252 | 0.373 | |||
| 1 | 13 (5.0%) | 7 | 6 | ||
| 2 | 78 (29.8%) | 50 | 28 | ||
| 3 | 103 (39.3%) | 64 | 39 | ||
| 4 | 27 (10.3%) | 12 | 15 | ||
| 5 | 41 (15.6%) | 22 | 19 | ||
| Pathological response | 0.366 | 0.545 | |||
| pCR | 54 (20.6%) | 30 | 24 | ||
| Non-pCR | 208 (79.4%) | 125 | 83 | ||
| Postoperative chemtherapy regimen | 1.618 | 0.899 | |||
| 0 | 146 (55.7%) | 85 | 61 | ||
| AC/ACF | 18 (6.9%) | 9 | 9 | ||
| CT/ACT | 17 (6.5%) | 10 | 7 | ||
| AT | 27 (10.3%) | 18 | 9 | ||
| TP | 21 (8.0%) | 12 | 9 | ||
| Others | 33 (12.6%) | 21 | 12 | ||
| Postoperative chemotherapy times | 1.294 | 0.523 | |||
| 0 | 146 (55.7%) | 85 | 61 | ||
| ＜4 | 41 (15.7%) | 22 | 19 | ||
| ≥4 | 75 (28.6%) | 48 | 27 |